What’s Propelling Vistagen Therapeutics Incorporated (NASDAQ:VTGN) After Higher Shorts Reported? – BZ Weekly

By admin

August 8, 2017 – By Peter Erickson

The stock of Vistagen Therapeutics Incorporated (NASDAQ:VTGN) registered an increase of 11.81% in short interest. VTGNs total short interest was 90,900 shares in August as published by FINRA. Its up 11.81% from 81,300 shares, reported previously. With 28,700 shares average volume, it will take short sellers 3 days to cover their VTGNs short positions. The short interest to Vistagen Therapeutics Incorporateds float is 1.75%.

The stock decreased 2.22% or $0.04 on August 7, reaching $1.76. About shares traded. Vistagen Therapeutics Inc (NASDAQ:VTGN) has declined 50.00% since August 8, 2016 and is downtrending. It has underperformed by 66.70% the S&P500.

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company has market cap of $16.74 million. The Firm is engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system . It currently has negative earnings. The Companys lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of major depressive disorder (MDD) in patients with an inadequate response to standard antidepressants approved by the United States Food and Drug Administration (FDA).

More notable recent Vistagen Therapeutics Inc (NASDAQ:VTGN) news were published by: Prnewswire.com which released: VistaGen Therapeutics Reports Second Quarter 2017 Financial Results and on November 14, 2016, also Finance.Yahoo.com with their article: VistaGen Therapeutics Receives European Patent Office Notice of Intention to published on March 29, 2017, Prnewswire.com published: VistaGen Therapeutics Grants Exclusive Sublicense of Cardiac Stem Cell on December 14, 2016. More interesting news about Vistagen Therapeutics Inc (NASDAQ:VTGN) were released by: Prnewswire.com and their article: VistaGen Therapeutics to Present at Biotech Showcase 2017 published on January 05, 2017 as well as Prnewswire.coms news article titled: VistaGen Therapeutics Provides Business Outlook and Sets Corporate Milestones with publication date: September 22, 2016.

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

More:
What’s Propelling Vistagen Therapeutics Incorporated (NASDAQ:VTGN) After Higher Shorts Reported? – BZ Weekly

Related Post


categoriaCardiac Stem Cells commentoComments Off on What’s Propelling Vistagen Therapeutics Incorporated (NASDAQ:VTGN) After Higher Shorts Reported? – BZ Weekly | dataAugust 11th, 2017

About...

This author published 2434 posts in this site.

Share

FacebookTwitterEmailWindows LiveTechnoratiDeliciousDiggStumbleponMyspaceLikedin

Comments are closed.





Personalized Gene Medicine | Mesenchymal Stem Cells | Stem Cell Treatment for Multiple Sclerosis | Stem Cell Treatments | Board Certified Stem Cell Doctors | Stem Cell Medicine | Personalized Stem Cells Therapy | Stem Cell Therapy TV | Individual Stem Cell Therapy | Stem Cell Therapy Updates | MD Supervised Stem Cell Therapy | IPS Stem Cell Org | IPS Stem Cell Net | Genetic Medicine | Gene Medicine | Longevity Medicine | Immortality Medicine | Nano Medicine | Gene Therapy MD | Individual Gene Therapy | Affordable Stem Cell Therapy | Affordable Stem Cells | Stem Cells Research | Stem Cell Breaking Research